Redeye updates its estimates on the back of I-Tech’s solid Q2-figures, posting an organic growth of 79%. Following the report, we raise our EBIT forecast by 5-7% for the two coming years while reminding that the regulatory process is highly important, and will most likely color the share price sentiment even though it has limited near-term financial effects. Following the latest conference call, we are becoming increasingly positive about I-Tech’s chances for a favorable outcome.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. www.redeye.se/
